查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088526

預防醫學市場：按產品類型、劑型、疾病領域和最終用戶分類的全球市場預測 – 2026-2032 年

Preventive Medicines Market by Product Type, Dosage Form, Disease Area, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，預防醫學市場將成長至 8,161 億美元，複合年成長率為 9.14%。

主要市場統計數據
基準年 2025 4422.7億美元
預計年份：2026年 4799.1億美元
預測年份 2032 8161億美元
複合年成長率 (%) 9.14%

預防醫學市場概覽

預防醫學正從狹隘地關注疫苗接種和預防措施，轉向更廣泛、基於循證醫學的模式，該模式涵蓋免疫接種、暴露前預防、化學預防、降低心血管代謝風險、婦幼保健干預以及以診斷技術為支撐的預防性治療。隨著慢性病和感染疾病仍然是可避免死亡的主要原因，而醫療系統又因晚期治療和可預防的住院治療而面臨成本增加，這一領域的重要性日益凸顯。

預防醫學領域的變革性變化

成人免疫接種、個人化風險分層、應對抗生素抗藥性的準備工作以及真實世界數據（REW）的日益普及，正在重新定義預防醫學領域。隨著癌症篩檢、心血管疾病預防、肥胖管理、婦幼保健和感染疾病預防與藥物取得、基層醫療工作流程和數位化病人參與日益融合，醫療保健系統正將早期療育置於優先地位。

人工智慧對預防醫學的累積影響

人工智慧 (AI) 透過改善標靶發現、臨床試驗設計、藥物安全監測、疾病監測、物資供應規劃和患者識別，正在增強預防醫學。機器學習模型可以分析保險理賠數據、電子健康記錄、基因組資訊和社會健康決定因素，從而識別高風險族群並支持早期療育。同時，人工智慧驅動的監測有助於更快發現集體爆發和疾病模式的變化。

預防醫學方面的關鍵區域見解

亞太地區因其龐大的人口基數、不斷擴展的免疫基礎設施以及日益成長的非傳染性疾病盛行率，被列為重點關注區域。中國、印度、日本、韓國和澳洲是疫苗、篩檢相關預防和慢性病風險降低領域的主要需求驅動力。北美仍然是創新和商業化的領先中心，這得益於先進的生命科學研發、以藥房為基礎的免疫接種、保險公司數據基礎設施、對成人免疫政策的重視以及在醫療決策中積極運用真實世界證據。

針對特定族群在預防醫學方面的關鍵見解：東協、海灣合作理事會、歐盟、金磚國家、七國集團、北約

東協市場對預防性藥物的重要性日益凸顯。這是因為各國政府在提高免疫接種率的同時，正透過基層醫療和公共衛生項目，積極推動糖尿病、高血壓、結核病、登革熱以及與年齡相關的疾病風險的防治工作。海灣合作理事會（GCC）成員國正透過國家層級的篩檢、數位健康平台、免疫宣傳活動和慢性病控制計畫來推廣預防性藥物，這反映了該地區心血管和代謝性疾病負擔沉重，以及其強大的公共投資能力。

各國預防性藥物的關鍵見解

美國透過投資生物技術、成人免疫基礎設施、藥局服務以及為保險公司提供分析工具，引領預防醫學創新。而加拿大則強調公共資助的免疫接種、健康公平和實證報銷。墨西哥和巴西是拉丁美洲的關鍵市場；墨西哥正透過公共衛生計畫加強預防工作，而巴西則利用其全國性的免疫接種能力和公共衛生體系的規模，支持涵蓋感染疾病和慢性病等重點領域的廣泛預防舉措。

為行業領導者提供的實用建議

產業領導者應優先進行證據收集工作，證明預防性藥物與降低疾病發生率、住院率、抗生素使用量、生產力下降以及長期醫療成本之間的關聯。打入市場策略應儘早制定，重點關注衛生經濟效益、公平取得、真實世界療效、安全性監測以及與國家免疫和預防指南的一致性。

調查方法

本執行摘要基於系統的二手研究方法，利用了來自世界衛生組織 (WHO)、美國疾病控制與預防中心 (CDC)、各國免疫規劃、監管機構、同行評審文獻、衛生技術評估 (HTA)研究途徑和衛生政策出版物等公開可靠的二手資訊。分析評估了預防性藥物在流行病學、可近性、報銷、創新、臨床證據和地方醫療保健系統優先事項等方面的部署。

結論

預防醫學正成為永續醫療保健的核心支柱，旨在疾病發生之前就加以控制，避免造成代價高昂的併發症。疫苗接種的有力證據、慢性病負擔的加重、人口老齡化、對抗生素抗藥性的擔憂以及向以價值觀為導向的醫療保健模式的轉變，都使得發達市場和新興市場對預防性干預措施的需求持續成長。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 預防醫學市場：依產品類型分類

  • 營養保健品
    • 草藥萃取物
    • 礦物
    • 維他命
  • 預防性藥物
    • 抗瘧疾藥
    • 抗病毒藥物
  • 疫苗
    • 去活化疫苗
    • 減毒活病毒疫苗
    • 重組疫苗

第8章 預防性藥物市場：依劑型分類

  • 注射藥物
    • 皮內注射
    • 肌肉內注射
    • 皮下注射
  • 口服
    • 膠囊
    • 糖漿
    • 藥片
  • 外用
    • 奶油
    • 凝膠
    • 修補

第9章 預防性藥物市場：依疾病領域分類

  • 癌症預防
  • 心血管系統
  • 感染疾病

第10章 預防醫學市場：依最終使用者分類

  • 家庭醫療保健
    • 專業服務
    • 自我管理
  • 醫院和診所
    • 私立醫院
    • 公立醫院
  • 研究機構
  • 疫苗接種中心

第11章 預防醫學市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章 預防醫學市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 預防醫學市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Abbott Laboratories
  • AliveCor, Inc
  • Amwell Corporation
  • Apple Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Becton, Dickinson and Company
  • CVS Health Corporation
  • Danaher Corporation
  • Dexcom, Inc.
  • F. Hoffmann-La Roche Ltd
  • Fitbit, Inc.
  • GlaxoSmithKline plc
  • Laboratory Corporation of America Holdings
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Omron Healthcare Co., Ltd.
  • Pfizer Inc.
  • Quest Diagnostics Incorporated
  • Sanofi SA
  • Siemens Healthineers AG
  • Teladoc Health, Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-031C6D6EB1CD

The Preventive Medicines Market is projected to grow by USD 816.10 billion at a CAGR of 9.14% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 442.27 billion
Estimated Year [2026] USD 479.91 billion
Forecast Year [2032] USD 816.10 billion
CAGR (%) 9.14%

Preventive Medicines Market Introduction

Preventive medicines are moving from a narrow focus on vaccination and prophylaxis to a broader evidence-based model that includes immunization, pre-exposure prophylaxis, chemoprevention, cardiometabolic risk reduction, maternal and child health interventions, and preventive therapies supported by diagnostics. The category is gaining strategic importance because chronic and infectious diseases continue to account for a large share of avoidable mortality, while health systems face rising costs from late-stage treatment and preventable hospital utilization.

The business case is strongly supported by public health data. The World Health Organization reports that immunization prevents an estimated 3.5 million to 5 million deaths each year, and the CDC notes that six in ten adults in the United States live with at least one chronic disease. These realities are increasing demand for preventive medicine strategies that lower disease incidence, improve population health outcomes, strengthen health system resilience, and reduce avoidable hospitalizations.

Transformative Shifts in the Preventive Medicines Landscape

The preventive medicines landscape is being reshaped by adult immunization, personalized risk stratification, antimicrobial resistance preparedness, and the growing use of real-world evidence. Health systems are prioritizing earlier intervention as cancer screening, cardiovascular prevention, obesity management, maternal health, and infectious disease prevention converge with pharmacy access, primary care workflows, and digital patient engagement.

A major shift is the expansion of prevention beyond pediatric programs. Aging populations, post-pandemic preparedness, and higher awareness of respiratory viruses are increasing demand for adult vaccines, long-acting prophylactic options, and prevention pathways integrated into routine care. At the same time, value-based care is pushing manufacturers and providers to demonstrate measurable reductions in disease burden, not only product utilization.

Cumulative Impact of Artificial Intelligence on Prevention

Artificial intelligence is strengthening preventive medicines by improving target discovery, clinical trial design, pharmacovigilance, disease surveillance, supply planning, and patient identification. Machine learning models can analyze claims, electronic health records, genomics, and social determinants of health to identify individuals at elevated risk and support earlier intervention, while AI-enabled surveillance can help detect outbreaks and changing disease patterns faster.

The cumulative impact is operational as well as clinical. AI can improve vaccine supply planning, reduce missed opportunities for preventive care, support personalized adherence programs, and help public health teams prioritize outreach to underserved populations. However, leaders must manage algorithmic bias, data privacy, explainability, and clinical validation because preventive decisions affect healthy or asymptomatic populations and therefore require particularly strong evidence and trust.

Key Regional Insights for Preventive Medicines

Asia-Pacific is a high-priority preventive medicines region due to large populations, expanding immunization infrastructure, and rising noncommunicable disease prevalence, with China, India, Japan, South Korea, and Australia shaping demand across vaccines, screening-linked prevention, and chronic disease risk reduction. North America remains a leading innovation and commercialization hub, supported by advanced life sciences R&D, pharmacy-based vaccination, payer data infrastructure, adult immunization policy attention, and strong use of real-world evidence in healthcare decision-making.

Europe benefits from established public health systems, centralized regulatory pathways, health technology assessment, and cross-border pharmacovigilance, while Latin America continues to expand vaccine access and primary care prevention despite uneven reimbursement and health system capacity. The Middle East is investing in preventive health as part of national transformation agendas, particularly in diabetes, cardiovascular disease, cancer screening, and infectious disease preparedness. Africa presents substantial long-term need and opportunity, driven by infectious disease burden, maternal and child health priorities, vaccine-preventable disease control, and the importance of resilient cold-chain, community delivery, and access models.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are increasingly important for preventive medicines because governments are expanding immunization coverage while addressing diabetes, hypertension, tuberculosis, dengue, and aging-related risks through primary care and public health programs. The GCC is advancing preventive health through national screening, digital health platforms, vaccination campaigns, and chronic disease programs, reflecting the region's high cardiometabolic burden and strong public investment capacity.

The European Union provides a structured environment for preventive medicine adoption through coordinated regulation, pharmacovigilance, joint health data initiatives, and public health collaboration, although country-level reimbursement still determines speed of uptake. BRICS countries combine major population scale with manufacturing capacity and growing domestic innovation, making them central to vaccine security, local production, and cost-effective prevention. G7 markets lead in premium innovation, real-world evidence, adult immunization policy, and health economic assessment, while NATO countries increasingly view biosecurity, pandemic preparedness, antimicrobial resistance readiness, and medical supply resilience as strategic priorities for national security and public health.

Key Country Insights for Preventive Medicines

The United States leads in preventive medicine innovation through biotechnology investment, adult immunization infrastructure, pharmacy access, and payer analytics, while Canada emphasizes publicly funded vaccination, health equity, and evidence-based reimbursement. Mexico and Brazil are important Latin American markets, with Mexico strengthening prevention through public health programs and Brazil's national immunization capabilities and public health scale supporting broad preventive initiatives across infectious and chronic disease priorities.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine mature regulatory oversight with strong demand for respiratory vaccines, cancer prevention, antimicrobial stewardship, and cardiometabolic risk management, while Russia maintains a sizable domestic pharmaceutical and vaccine ecosystem. China and India are pivotal to global preventive medicine volume, manufacturing, and access, with China scaling biotechnology innovation and population health programs and India remaining a major vaccine supplier with expanding domestic prevention needs. Japan, Australia, and South Korea are advanced prevention markets supported by aging populations, strong clinical standards, national immunization programs, screening infrastructure, and high digital health readiness.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence generation that links preventive medicines to reductions in disease incidence, hospitalization, antimicrobial use, productivity loss, and long-term health expenditure. Market access strategies should be built early around health economic outcomes, equity of access, real-world effectiveness, safety monitoring, and alignment with national immunization or prevention guidelines.

Organizations should also invest in adult prevention pathways, pharmacy and primary care partnerships, cold-chain resilience, digital adherence tools, and AI-enabled patient identification. For global growth, leaders need differentiated strategies for high-income markets focused on value demonstration and emerging markets focused on affordability, supply reliability, local partnerships, technology transfer readiness, and public procurement alignment.

Research Methodology

This executive summary is based on a structured secondary research approach using publicly available and authoritative sources, including the World Health Organization, Centers for Disease Control and Prevention, national immunization programs, regulatory agencies, peer-reviewed literature, health technology assessment documents, and health policy publications. The analysis evaluates preventive medicine adoption across epidemiology, access, reimbursement, innovation, clinical evidence, and regional health system priorities.

The methodology applies cross-validation across multiple source categories to reduce bias and ensure factual consistency. Insights were organized by region, economic grouping, and priority country to support search relevance and strategic decision-making for stakeholders in pharmaceuticals, biotechnology, healthcare delivery, diagnostics, payers, procurement agencies, and public health.

Conclusion

Preventive medicines are becoming a core pillar of sustainable healthcare because they address disease before costly complications occur. Strong evidence for vaccination, rising chronic disease burden, population aging, antimicrobial resistance concerns, and the shift toward value-based care are creating durable demand for preventive interventions across both developed and emerging markets.

The next stage of leadership will depend on trusted evidence, equitable access, resilient supply chains, responsible use of AI, and close integration with public health priorities. Organizations that connect innovation with measurable prevention outcomes will be best positioned to improve population health and build long-term relevance in the preventive medicines market.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Preventive Medicines Market, by Product Type

  • 7.1. Nutraceuticals
    • 7.1.1. Herbal Extracts
    • 7.1.2. Minerals
    • 7.1.3. Vitamins
  • 7.2. Prophylactic Drugs
    • 7.2.1. Antimalarials
    • 7.2.2. Antivirals
  • 7.3. Vaccines
    • 7.3.1. Inactivated Vaccines
    • 7.3.2. Live Attenuated
    • 7.3.3. Recombinant

8. Preventive Medicines Market, by Dosage Form

  • 8.1. Injectable
    • 8.1.1. Intradermal
    • 8.1.2. Intramuscular
    • 8.1.3. Subcutaneous
  • 8.2. Oral
    • 8.2.1. Capsules
    • 8.2.2. Syrups
    • 8.2.3. Tablets
  • 8.3. Topical
    • 8.3.1. Creams
    • 8.3.2. Gels
    • 8.3.3. Patches

9. Preventive Medicines Market, by Disease Area

  • 9.1. Cancer Prevention
  • 9.2. Cardiovascular
  • 9.3. Infectious Disease

10. Preventive Medicines Market, by End User

  • 10.1. Home Healthcare
    • 10.1.1. Professional Services
    • 10.1.2. Self Administration
  • 10.2. Hospitals And Clinics
    • 10.2.1. Private Hospitals
    • 10.2.2. Public Hospitals
  • 10.3. Research Institutions
  • 10.4. Vaccination Centers

11. Preventive Medicines Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Preventive Medicines Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Preventive Medicines Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Concentration Analysis, 2025
    • 14.1.1. Concentration Ratio (CR)
    • 14.1.2. Herfindahl Hirschman Index (HHI)
  • 14.2. Recent Developments & Impact Analysis, 2025
  • 14.3. Product Portfolio Analysis, 2025
  • 14.4. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Abbott Laboratories
  • 15.2. AliveCor, Inc
  • 15.3. Amwell Corporation
  • 15.4. Apple Inc.
  • 15.5. AstraZeneca PLC
  • 15.6. Bayer AG
  • 15.7. Becton, Dickinson and Company
  • 15.8. CVS Health Corporation
  • 15.9. Danaher Corporation
  • 15.10. Dexcom, Inc.
  • 15.11. F. Hoffmann-La Roche Ltd
  • 15.12. Fitbit, Inc.
  • 15.13. GlaxoSmithKline plc
  • 15.14. Laboratory Corporation of America Holdings
  • 15.15. Merck & Co., Inc.
  • 15.16. Moderna, Inc.
  • 15.17. Omron Healthcare Co., Ltd.
  • 15.18. Pfizer Inc.
  • 15.19. Quest Diagnostics Incorporated
  • 15.20. Sanofi S.A.
  • 15.21. Siemens Healthineers AG
  • 15.22. Teladoc Health, Inc.
  • 15.23. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PREVENTIVE MEDICINES MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL PREVENTIVE MEDICINES MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL PREVENTIVE MEDICINES MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL PREVENTIVE MEDICINES MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL PREVENTIVE MEDICINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL PREVENTIVE MEDICINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NUTRACEUTICALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NUTRACEUTICALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NUTRACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HERBAL EXTRACTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HERBAL EXTRACTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HERBAL EXTRACTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MINERALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MINERALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MINERALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VITAMINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VITAMINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VITAMINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PROPHYLACTIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PROPHYLACTIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PROPHYLACTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTIMALARIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIMALARIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTIMALARIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIVIRALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTIVIRALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INACTIVATED VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INACTIVATED VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INACTIVATED VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LIVE ATTENUATED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LIVE ATTENUATED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LIVE ATTENUATED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RECOMBINANT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RECOMBINANT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RECOMBINANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INTRADERMAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INTRADERMAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INTRADERMAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SYRUPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SYRUPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SYRUPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CREAMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CREAMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CREAMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PATCHES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PATCHES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CANCER PREVENTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER PREVENTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CANCER PREVENTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HOME HEALTHCARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HOME HEALTHCARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HOME HEALTHCARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PROFESSIONAL SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PROFESSIONAL SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PROFESSIONAL SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL SELF ADMINISTRATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL SELF ADMINISTRATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL SELF ADMINISTRATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL HOSPITALS AND CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HOSPITALS AND CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL HOSPITALS AND CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL RESEARCH INSTITUTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL RESEARCH INSTITUTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL RESEARCH INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL VACCINATION CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL VACCINATION CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL VACCINATION CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY PROPHYLACTIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY HOME HEALTHCARE, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA PREVENTIVE MEDICINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY PROPHYLACTIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY HOME HEALTHCARE, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA PREVENTIVE MEDICINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY PROPHYLACTIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY HOME HEALTHCARE, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE PREVENTIVE MEDICINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE PREVENTIVE MEDICINES MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE PREVENTIVE MEDICINES MARKET SIZE, BY PROPHYLACTIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE PREVENTIVE MEDICINES MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE PREVENTIVE MEDICINES MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE PREVENTIVE MEDICINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE PREVENTIVE MEDICINES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE PREVENTIVE MEDICINES MARKET SIZE, BY HOME HEALTHCARE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE PREVENTIVE MEDICINES MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST PREVENTIVE MEDICINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST PREVENTIVE MEDICINES MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST PREVENTIVE MEDICINES MARKET SIZE, BY PROPHYLACTIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST PREVENTIVE MEDICINES MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST PREVENTIVE MEDICINES MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST PREVENTIVE MEDICINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST PREVENTIVE MEDICINES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST PREVENTIVE MEDICINES MARKET SIZE, BY HOME HEALTHCARE, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST PREVENTIVE MEDICINES MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA PREVENTIVE MEDICINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY PROPHYLACTIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY HOME HEALTHCARE, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN PREVENTIVE MEDICINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN PREVENTIVE MEDICINES MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN PREVENTIVE MEDICINES MARKET SIZE, BY PROPHYLACTIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN PREVENTIVE MEDICINES MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN PREVENTIVE MEDICINES MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN PREVENTIVE MEDICINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN PREVENTIVE MEDICINES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN PREVENTIVE MEDICINES MARKET SIZE, BY HOME HEALTHCARE, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN PREVENTIVE MEDICINES MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 201. GCC PREVENTIVE MEDICINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 202. GCC PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. GCC PREVENTIVE MEDICINES MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 204. GCC PREVENTIVE MEDICINES MARKET SIZE, BY PROPHYLACTIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 205. GCC PREVENTIVE MEDICINES MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 206. GCC PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 207. GCC PREVENTIVE MEDICINES MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 208. GCC PREVENTIVE MEDICINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 209. GCC PREVENTIVE MEDICINES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 210. GCC PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 211. GCC PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. GCC PREVENTIVE MEDICINES MARKET SIZE, BY HOME HEALTHCARE, 2018-2032 (USD MILLION)
  • TABLE 213. GCC PREVENTIVE MEDICINES MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION PREVENTIVE MEDICINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION PREVENTIVE MEDICINES MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION PREVENTIVE MEDICINES MARKET SIZE, BY PROPHYLACTIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION PREVENTIVE MEDICINES MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION PREVENTIVE MEDICINES MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION PREVENTIVE MEDICINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION PREVENTIVE MEDICINES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION PREVENTIVE MEDICINES MARKET SIZE, BY HOME HEALTHCARE, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION PREVENTIVE MEDICINES MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS PREVENTIVE MEDICINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS PREVENTIVE MEDICINES MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS PREVENTIVE MEDICINES MARKET SIZE, BY PROPHYLACTIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS PREVENTIVE MEDICINES MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS PREVENTIVE MEDICINES MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS PREVENTIVE MEDICINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS PREVENTIVE MEDICINES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS PREVENTIVE MEDICINES MARKET SIZE, BY HOME HEALTHCARE, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS PREVENTIVE MEDICINES MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 240. G7 PREVENTIVE MEDICINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 241. G7 PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. G7 PREVENTIVE MEDICINES MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 243. G7 PREVENTIVE MEDICINES MARKET SIZE, BY PROPHYLACTIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 244. G7 PREVENTIVE MEDICINES MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 245. G7 PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 246. G7 PREVENTIVE MEDICINES MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 247. G7 PREVENTIVE MEDICINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 248. G7 PREVENTIVE MEDICINES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 249. G7 PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 250. G7 PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. G7 PREVENTIVE MEDICINES MARKET SIZE, BY HOME HEALTHCARE, 2018-2032 (USD MILLION)
  • TABLE 252. G7 PREVENTIVE MEDICINES MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 253. NATO PREVENTIVE MEDICINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. NATO PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. NATO PREVENTIVE MEDICINES MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 256. NATO PREVENTIVE MEDICINES MARKET SIZE, BY PROPHYLACTIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 257. NATO PREVENTIVE MEDICINES MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 258. NATO PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 259. NATO PREVENTIVE MEDICINES MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 260. NATO PREVENTIVE MEDICINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 261. NATO PREVENTIVE MEDICINES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 262. NATO PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 263. NATO PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. NATO PREVENTIVE MEDICINES MARKET SIZE, BY HOME HEALTHCARE, 2018-2032 (USD MILLION)
  • TABLE 265. NATO PREVENTIVE MEDICINES MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 266. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY PROPHYLACTIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY HOME HEALTHCARE, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 280. CANADA PREVENTIVE MEDICINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 281. CANADA PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. CANADA PREVENTIVE MEDICINES MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 283. CANADA PREVENTIVE MEDICINES MARKET SIZE, BY PROPHYLACTIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 284. CANADA PREVENTIVE MEDICINES MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 285. CANADA PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 286. CANADA PREVENTIVE MEDICINES MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 287. CANADA PREVENTIVE MEDICINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 288. CANADA PREVENTIVE MEDICINES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 289. CANADA PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 290. CANADA PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 291. CANADA PREVENTIVE MEDICINES MARKET SIZE, BY HOME HEALTHCARE, 2018-2032 (USD MILLION)
  • TABLE 292. CANADA PREVENTIVE MEDICINES MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 293. MEXICO PREVENTIVE MEDICINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 294. MEXICO PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. MEXICO PREVENTIVE MEDICINES MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 296. MEXICO PREVENTIVE MEDICINES MARKET SIZE, BY PROPHYLACTIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 297. MEXICO PREVENTIVE MEDICINES MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 298. MEXICO PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 299. MEXICO PREVENTIVE MEDICINES MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 300. MEXICO PREVENTIVE MEDICINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 301. MEXICO PREVENTIVE MEDICINES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 302. MEXICO PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 303. MEXICO PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 304. MEXICO PREVENTIVE MEDICINES MARKET SIZE, BY HOME HEALTHCARE, 2018-2032 (USD MILLION)
  • TABLE 305. MEXICO PREVENTIVE MEDICINES MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 306. BRAZIL PREVENTIVE MEDICINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 307. BRAZIL PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 308. BRAZIL PREVENTIVE MEDICINES MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 309. BRAZIL PREVENTIVE MEDICINES MARKET SIZE, BY PROPHYLACTIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 310. BRAZIL PREVENTIVE MEDICINES MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 311. BRAZIL PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 312. BRAZIL PREVENTIVE MEDICINES MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 313. BRAZIL PREVENTIVE MEDICINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 314. BRAZIL PREVENTIVE MEDICINES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 315. BRAZIL PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 316. BRAZIL PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 317. BRAZIL PREVENTIVE MEDICINES MARKET SIZE, BY HOME HEALTHCARE, 2018-2032 (USD MILLION)
  • TABLE 318. BRAZIL PREVENTIVE MEDICINES MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED KINGDOM PREVENTIVE MEDICINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED KINGDOM PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED KINGDOM PREVENTIVE MEDICINES MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED KINGDOM PREVENTIVE MEDICINES MARKET SIZE, BY PROPHYLACTIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED KINGDOM PREVENTIVE MEDICINES MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED KINGDOM PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED KINGDOM PREVENTIVE MEDICINES MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 326. UNITED KINGDOM PREVENTIVE MEDICINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 327. UNITED KINGDOM PREVENTIVE MEDICINES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 328. UNITED KINGDOM PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 329. UNITED KINGDOM PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 330. UNITED KINGDOM PREVENTIVE MEDICINES MARKET SIZE, BY HOME HEALTHCARE, 2018-2032 (USD MILLION)
  • TABLE 331. UNITED KINGDOM PREVENTIVE MEDICINES MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 332. GERMANY PREVENTIVE MEDICINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 333. GERMANY PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 334. GERMANY PREVENTIVE MEDICINES MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 335. GERMANY PREVENTIVE MEDICINES MARKET SIZE, BY PROPHYLACTIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 336. GERMANY PREVENTIVE MEDICINES MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 337. GERMANY PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 338. GERMANY PREVENTIVE MEDICINES MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 339. GERMANY PREVENTIVE MEDICINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 340. GERMANY PREVENTIVE MEDICINES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 341. GERMANY PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 342. GERMANY PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 343. GERMANY PREVENTIVE MEDICINES MARKET SIZE, BY HOME HEALTHCARE, 2018-2032 (USD MILLION)
  • TABLE 344. GERMANY PREVENTIVE MEDICINES MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 345. FRANCE PREVENTIVE MEDICINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 346. FRANCE PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 347. FRANCE PREVENTIVE MEDICINES MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 348. FRANCE PREVENTIVE MEDICINES MARKET SIZE, BY PROPHYLACTIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 349. FRANCE PREVENTIVE MEDICINES MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 350. FRANCE PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 351. FRANCE PREVENTIVE MEDICINES MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 352. FRANCE PREVENTIVE MEDICINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 353. FRANCE PREVENTIVE MEDICINES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 354. FRANCE PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 355. FRANCE PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 356. FRANCE PREVENTIVE MEDICINES MARKET SIZE, BY HOME HEALTHCARE, 2018-2032 (USD MILLION)
  • TABLE 357. FRANCE PREVENTIVE MEDICINES MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 358. RUSSIA PREVENTIVE MEDICINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 359. RUSSIA PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 360. RUSSIA PREVENTIVE MEDICINES MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 361. RUSSIA PREVENTIVE MEDICINES MARKET SIZE, BY PROPHYLACTIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 362. RUSSIA PREVENTIVE MEDICINES MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 363. RUSSIA PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 364. RUSSIA PREVENTIVE MEDICINES MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 365. RUSSIA PREVENTIVE MEDICINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 366. RUSSIA PREVENTIVE MEDICINES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 367. RUSSIA PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 368. RUSSIA PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2018